← Back to Clinical Trials
Recruiting NCT06464042

NCT06464042 Influence of Air Quality on the Development and Progression of Premature Coronary Artery Disease

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06464042
Status Recruiting
Phase
Sponsor pablo Juan-Salvadores
Condition Coronary Artery Disease Premature
Study Type OBSERVATIONAL
Enrollment 4,272 participants
Start Date 2024-05-23
Primary Completion 2024-12-31

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age 40 Years
Study Type OBSERVATIONAL

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 4,272 participants in total. It began in 2024-05-23 with a primary completion date of 2024-12-31.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The new global guidelines from the World Health Organization on air quality provide evidence of the damage that air pollution inflicts on human health at even lower concentrations than previously thought. Different studies have shown an increase in the incidence of coronary artery disease (CAD) in young people in recent decades. The main objective of this project is to study the impact of environmental pollutants on the premature manifestation of CAD from different epidemiological approaches and their impact on the evolution of these patients with a gender perspective. It is a retrospective analytical case-control study nested in a cohort of patients ≤40 years old with a clinical history of CAD including: ST-segment elevation myocardial infarction, non-ST-segment elevation acute coronary syndrome, unstable angina, stable angina or silent angina according to the international classification of diseases.

Eligibility Criteria

CASES: Inclusion Criteria: * Women and men between 18 and 40 years old with a diagnosis of coronary artery disease coded in their medical records in Galicia Exclusion Criteria: * Not having a postal code and primary care center assigned in their medical records in Galicia CONTROL Inclusion Criteria: * Women and men between 18 and 40 years old with no diagnosis or history of CAD or other coronary disease coded in their medical records Exclusion Criteria: * Present with non-ischemic coronary diseas. * Have a serious condition that affects or decreases life expectancy. * Do not have a postal code or primary care center assigned in their medical records in Galicia

Contact & Investigator

Central Contact

Pablo Juan-Salvadores, Pharma, PhD

✉ pablo.juan@iisgaliciasur.es

📞 +34986825564

Principal Investigator

Pablo Juan-Salvadores, Pharma, PhD

PRINCIPAL INVESTIGATOR

Instituto de Investigación Sanitaria Galicia Sur (IIS Galicia Sur)

Frequently Asked Questions

Who can join the NCT06464042 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, up to 40 Years, studying Coronary Artery Disease Premature. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06464042 currently recruiting?

Yes, NCT06464042 is actively recruiting participants. Contact the research team at pablo.juan@iisgaliciasur.es for enrollment information.

Where is the NCT06464042 trial being conducted?

This trial is being conducted at Vigo, Spain.

Who is sponsoring the NCT06464042 clinical trial?

NCT06464042 is sponsored by pablo Juan-Salvadores. The principal investigator is Pablo Juan-Salvadores, Pharma, PhD at Instituto de Investigación Sanitaria Galicia Sur (IIS Galicia Sur). The trial plans to enroll 4,272 participants.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology